CAYSTON
CAYSTON (aztreonam) is a monobactam antibacterial indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with *Pseudomonas aeruginosa*. To reduce the development of drug-resistant bacteria and maintain the effectiveness of the treatment, CAYSTON should only be used in patients known to have *P. aeruginosa* in the lungs. Safety and effectiveness have not been established in pediatric patients under 7 years of age, patients with a predicted FEV1 <25% or >75%, or patients colonized with *Burkholderia cepacia*.
How CAYSTON Works
Aztreonam is a monobactam antibiotic that inhibits bacterial cell wall synthesis. It exhibits potent activity in vitro against Gram-negative aerobic pathogens, including *Pseudomonas aeruginosa*. Aztreonam binds to penicillin-binding protein 3 (PBP3) of susceptible bacteria, which inhibits the third and last stage of bacterial cell wall synthesis. This interference leads to the inhibition of peptidoglycan assembly, resulting in bacterial cell filamentation, lysis, and death. Aztreonam is poorly absorbed systemically when inhaled, allowing for high local concentrations in the lungs.
Details
- Status
- Prescription
- First Approved
- 2010-02-22
- Routes
- INHALATION
- Dosage Forms
- FOR SOLUTION
CAYSTON Approval History
What CAYSTON Treats
1 indicationsCAYSTON is approved for 1 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Cystic Fibrosis
Drugs Similar to CAYSTON
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CAYSTON FDA Label Details
ProIndications & Usage
FDA Label (PDF)CAYSTON ® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa . Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV 1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pseudomonas aeruginosa in the lungs. CAYSTON is a monobactam antibacteri...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.